d as similar life expectancies due to the much earlier presentation.Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to investigate whether a patient registry can complement or even replace postapproval trials. Postapproval single-arm clinical trial data from the Medicines Evaluation Board and real-world data from the Dutch Melanoma Treatment Registry were used. The study population consisted of advanced melanoma patients with brain metastases treated with targeted therapies (BRAF- or BRAF-MEK inhibitors) in the first line. A Cox hazard regression model and a propensity score matching (PSM) model were used to compare the two patient populations. Compared to patients treated in postapproval trials (n = 467), real-world patients (n = 602) had significantly higher age, higher ECOG performance status, more often ≥3 organ involvement and more symptomatic brain metastases. Lactate dehydrogenase levels were similar between both groups. The unadjusted median overall survival (mOS) in postapproval clinical trial patients was 8.7 (95% CI, 8.1-10.4) months compared to 7.2 (95% CI, 6.5-7.7) months (P  less then  0.01) in real-world patients. With the Cox hazard regression model, survival was adjusted for prognostic factors, which led to a statistically insignificant difference in mOS for trial and real-world patients of 8.7 (95% CI, 7.9-10.4) months compared to 7.3 (95% CI, 6.3-7.9) months, respectively. The PSM model resulted in 310 matched patients with similar survival (P = 0.9). Clinical outcomes of both data sources were similar. https://www.selleckchem.com/products/ly2157299.html Registries could be a complementary data source to postapproval clinical trials to establish information on clinical outcomes in specific subpopulations. Surgery-related pressure injury (SRPI) is a serious problem in patients who undergo cardiovascular surgery. Identifying patients at a high risk of SRPI is important for clinicians to recognize and prevent it expeditiously. Machine learning (ML) has been widely used in the field of healthcare and is well suited to predictive analysis. The aim of this study was to develop an ML-based predictive model for SRPI in patients undergoing cardiovascular surgery. This secondary analysis of data was based on a single-center, prospective cohort analysis of 149 patients who underwent cardiovascular surgery. Data were collected from a 1,000-bed university-affiliated hospital. We developed the ML model using the XGBoost algorithm for SRPI prediction in patients undergoing cardiovascular surgery based on major potential risk factors. Model performance was tested using a receiver operating characteristic curve and the C-index. Of the sample of 149 patients, SRPI developed in 37, an incidence rate of 24.8%. The five most important predictors included duration of surgery, patient weight, duration of the cardiopulmonary bypass procedure, patient age, and disease category. The ML model had an area under the receiver operating characteristic curve of 0.806, which indicates that the ML model has a moderate prediction value for SRPI. Applying ML to clinical data may be a reliable approach to the assessment of the risk of SRPI in patients undergoing cardiovascular surgical procedures. Future studies may deploy the ML model in the clinic and focus on applying targeted interventions for SRPI and related diseases. Applying ML to clinical data may be a reliable approach to the assessment of the risk of SRPI in patients undergoing cardiovascular surgical procedures. Future studies may deploy the ML model in the clinic and focus on applying targeted interventions for SRPI and related diseases. Microvasculature dropout (MvD) is a novel finding seen in optical coherence tomography angiography (OCTA), which is characterized by a localized dehiscence of the choriocapillaris in the parapapillary atrophy area. Disc hemorrhage (DH) is an important factor often associated with the development and especially progression of glaucoma. Here, we present 2 cases of MvD progression with DH. Case 1 A 62-year-old female patient with normal tension glaucoma in both her eyes had recurrent DH at the inferior area of her right eye. A new DH was observed in the inferotemporal area of the right eye with MvD progression on OCTA in the same direction three months from the baseline.Case 2 A 57-year-old female patient with bilateral steroid-induced secondary glaucoma also had recurrent DH in her right eye. Four months from the baseline, DH occurred in the superotemporal and inferotemporal area of the right eye, and MvD was detected on OCTA in the superotemporal corresponding direction. After 19 months from the baseline, OCTA was repeated. The DH had resolved, but the superotemporal MvD persisted. The 2 cases presented here are the first to report on the relationship between MvD progression and DH. MvD as visualized in OCTA imaging looks to be of clinical importance, and hopefully future studies will reveal the actual connection between MvD, DH, and glaucoma progression. The 2 cases presented here are the first to report on the relationship between MvD progression and DH. MvD as visualized in OCTA imaging looks to be of clinical importance, and hopefully future studies will reveal the actual connection between MvD, DH, and glaucoma progression. In African American patients with glaucoma, iStent/phacoemulsification lowered intraocular pressure and reduced glaucoma medication usage for up to 1 year, even in patients with prior selective laser trabeculoplasty (SLT). Currently, no studies have examined the outcomes of a trabecular microbypass stent and phacoemulsification in African American patients. Here, the authors investigate whether iStent/phacoemulsification decreases intraocular pressure (IOP) and/or medication usage in African American patients with glaucoma. They are also interested in whether prior SLT would affect outcomes of iStent/phacoemulsification. A multicenter, retrospective case series of eyes that underwent iStent/phacoemulsification between 2013 and 2017 with up to 1-year follow-up. Eyes with a confirmed diagnosis of glaucoma in African American patients were included. Eyes with neovascular glaucoma or closed angle glaucoma and eyes that underwent previous incisional glaucoma surgery were excluded. Eighty-nine eyes were included in the study and data for 66 eyes were available at postoperative year 1 (POY1).